Drug Trial Radar · NCT07935031
A Study of IMS001 in Patients With Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
4
Planned (sponsor's estimate)
Start
Sep 28, 2026
Primary completion
Dec 2027
Study completion Dec 2029
Sponsor
- Lead sponsor
- Zhuhai Hengqin ImStem Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and tolerability of IMS001 and explore its possible effects in adults with multiple sclerosis. IMS001 is an investigational cell therapy consisting of mesenchymal-like stem cells derived from human embryonic stem cells. The study plans to enroll 4 adults aged 18 to 65 years with relapsing-remitting or secondary progressive multiple sclerosis in China. Each participant will receive a single infusion of IMS001 into a vein. All participants will receive IMS001, and both participants and the study team will know which treatment is given. Participants will undergo screening for up to 4 weeks before treatment. After the infusion, they will be assessed over 12 months for side effects and changes in multiple sclerosis, including relapses, disability, brain magnetic resonance imaging (MRI) findings, vision, movement, and thinking abilities. Participants will then enter an additional 24-month follow-up period to monitor long-term safety, including serious side effects and possible tumor development. Total participation may last up to 37 months, including screening.
Conditions
- Multiple Sclerosis
Interventions
IMS001Biological
IMS001 is a human embryonic stem cell-derived mesenchymal-like stem cell product. Each participant will receive a single intravenous infusion at a dose of 1 × 10\^6 cells/kg on Day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With IMS001-Related Adverse EventsTime frame: From IMS001 infusion on Day 1 through Month 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital, Sichuan University
Chengdu, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.